Bioxytran, Inc.
Bioxytran, Inc.
- Market cap
- $3.65M
Your view on BIXT
Overview
What the company does, where it operates, and who runs it.
About Bioxytran, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Platt
- Headquarters
- 233 Needham Street, Newton, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Platt
- Headquarters
- 233 Needham Street, Newton, MA, US
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans.
The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Bioxytran, Inc.. Starting points for Bioxytran, Inc.: EPS -$0.03, beta 2.08 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Bioxytran, Inc.. Bioxytran, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Bioxytran, Inc.. Trailing twelve-month EPS for Bioxytran, Inc. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Bioxytran, Inc.. Bioxytran, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BETRFBetterLife Pharma Inc. | Healthcare | Biotechnology | $6.4M | ||
| BVAXFBioVaxys Technology Corp. | Healthcare | Biotechnology | $3.1M | ||
| BZYRBurzynski Research Institute, Inc. | Healthcare | Medical - Pharmaceuticals | $3.4M | ||
| CPMVMosaic ImmunoEngineering Inc. | Healthcare | Biotechnology | $2.9M | ||
| GLWLFGlow Lifetech Corp. | Healthcare | Biotechnology | $6.7M | ||
| KNBIFKane Biotech Inc. | Healthcare | Biotechnology | $4.6M | ||
| MYNDFMYND Life Sciences Inc. | Healthcare | Biotechnology | $657,843 | ||
| NSHSFNanoSphere Health Sciences Inc. | Healthcare | Biotechnology | $102,752 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ERASErasca, Inc. | Healthcare | NASDAQ | $4.8B | ||
| ERNAErnexa Therapeutics Inc. | Healthcare | NASDAQ | $2.3M | ||
| ERNAWErnexa Therapeutics Inc. Warrants | Healthcare | NASDAQ | $201,824 | ||
| ESLAEstrella Immunopharma, Inc. | Healthcare | NASDAQ | $14.1M | ||
| ESLAWEstrella Immunopharma, Inc. | Healthcare | NASDAQ | $19.4M | ||
| EVAXEvaxion Biotech A/S | Healthcare | NASDAQ | $14.2M | ||
| EVFMEvofem Biosciences, Inc. | Healthcare | OTC | $1.2M | ||
| EVGNEvogene Ltd. | Healthcare | NASDAQ | $2.7M | ||
| EVLOEvelo Biosciences, Inc. | Healthcare | OTC | $1,898 | ||
| EVMNEvommune, Inc. | Healthcare | NYSE | $291.1M | ||
| EWTXEdgewise Therapeutics, Inc. | Healthcare | NASDAQ | $4.3B | ||
| EXELExelixis, Inc. | Healthcare | NASDAQ | $16.2B | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Bioxytran, Inc. executives and directors. Shares of Bioxytran, Inc. have traded between $0.03 and $0.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Bioxytran, Inc.. Coverage tracks Bioxytran, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Bioxytran, Inc.